Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study-Reference-Cited by-同舟云学术

Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study

Published:2022-08-26 Issue:12 Volume:52 Page:975-984
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Yun Byungyoon¹,Ahn Sang Hoon²³⁴,Oh Juyeon⁵,Yoon Jin‐Ha¹⁶,Kim Beom Kyung²³⁴

Affiliation:

1. Department of Preventive Medicine Yonsei University College of Medicine Seoul Korea

2. Department of Internal Medicine Yonsei University College of Medicine Seoul Korea

3. Institute of Gastroenterology Yonsei University College of Medicine Seoul Korea

4. Yonsei Liver Center Severance Hospital Yonsei University Health System Seoul Korea

5. Department of Public Health Graduate School Yonsei University Seoul Korea

6. Department of Occupational Health Department of Preventive Medicine Yonsei University College of Medicine Seoul Korea

Funder

Korea Health Industry Development Institute

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13830

Reference39 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

3. MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients;Hepatology International;2024-07-16

2. The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients;Hepatology International;2024-06-27

3. Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level;Heliyon;2024-06

4. Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!’;Journal of Hepatology;2024-06

5. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study;Frontiers in Physiology;2024-02-09